ISAB receives significant capital investment from new minority shareholders
ISAB is broadening its ownership base with a significant initial capital investment from prestigious venture finance companies Stockholms Affärsänglar (STOAF) and Almi Invest, who both become new minority share owners. The new ownership and investment reflects ISABs strategy of commercializing its world-leading technology platform for inhalation R&D.
Read the official Press Release: ISAB Press Release 25.06.2015 New Investors
The capital investment is the first phase of a three-phase investment in ISAB. Fredrik Sjövall, ISAB CEO: “We see increased possibilities from this broadening of our ownership base. Stockholm Business Angels’ and Almi’s expertise and network will help us realize and speed up the commercialization of our products following the first rollouts of our technology. Getting new owners onboard underlines the growing potential, scalability and exceptional technological caliber of our products.”
Almi Invest Investment Manager Claes Post: “Thanks to Inhalation Sciences’ technology platform the costs of developing treatments for a range of lung diseases can be significantly reduced. The consumption of expensive test substances during development can be minimized and the precision of the data generated dramatically improved. The pharmaceutical industry has a great need to reduce their development costs while still producing effective treatments against lung disease.”
STOAF CEO Klaus Gottwald: “With ISAB we have added another medtech venture to our portfolio of companies with a strong science and technology profile. STOAF will contribute to ISAB’s development through new input in both funding and competence. With our strong international network of business contacts we look forward to helping ISAB establish itself in both Asia and the US.”
ISAB receives significant capital investment from new minority shareholders
ISAB is broadening its ownership base with a significant initial capital investment from prestigious venture finance companies Stockholms Affärsänglar (STOAF) and Almi Invest, who both become new minority share owners. The new ownership and investment reflects ISABs strategy of commercializing its world-leading technology platform for inhalation R&D.
Read the official Press Release: ISAB Press Release 25.06.2015 New Investors
The capital investment is the first phase of a three-phase investment in ISAB. Fredrik Sjövall, ISAB CEO: “We see increased possibilities from this broadening of our ownership base. Stockholm Business Angels’ and Almi’s expertise and network will help us realize and speed up the commercialization of our products following the first rollouts of our technology. Getting new owners onboard underlines the growing potential, scalability and exceptional technological caliber of our products.”
Almi Invest Investment Manager Claes Post: “Thanks to Inhalation Sciences’ technology platform the costs of developing treatments for a range of lung diseases can be significantly reduced. The consumption of expensive test substances during development can be minimized and the precision of the data generated dramatically improved. The pharmaceutical industry has a great need to reduce their development costs while still producing effective treatments against lung disease.”
STOAF CEO Klaus Gottwald: “With ISAB we have added another medtech venture to our portfolio of companies with a strong science and technology profile. STOAF will contribute to ISAB’s development through new input in both funding and competence. With our strong international network of business contacts we look forward to helping ISAB establish itself in both Asia and the US.”
